Literature DB >> 10361518

Serum alpha-fetoprotein levels in patients with chronic hepatitis C. Relationships with serum alanine aminotransferase values, histologic activity index, and hepatocyte MIB-1 scores.

N S Goldstein1, D E Blue, R Hankin, S Hunter, N Bayati, A L Silverman, S C Gordon.   

Abstract

Patients with chronic viral hepatitis and cirrhosis often have elevated serum alpha-fetoprotein (AFP) values, the causes of which are unclear. We studied 81 patients with chronic hepatitis C and the relationships of serum AFP and alanine aminotransferase (ALT) values, hepatic histologic features, and hepatocyte proliferation activity scores. Twenty-two patients had nil to mild fibrosis, 34 had moderate fibrosis, and 25 had marked fibrosis-cirrhosis. The mean serum AFP value was significantly greater in patients with more fibrosis. Serum ALT values were slightly greater in the marked fibrosis-cirrhosis patient group. The differences in the HAI and in hepatocyte MIB-1 scores were not significant. Among all patients, increasing serum AFP values significantly correlated with increasing ALT values. However, there were no significant correlations with serum ALT or HAI and serum AFP values. There was no association between serum AFP values and immunohistochemical staining for AFP within hepatocytes. These results suggest that elevated serum AFP values are the result of altered hepatocyte-hepatocyte interaction and loss of normal architectural arrangements. The presence of marked fibrosis or cirrhosis, a state of significant altered hepatocyte architecture, may be the underlying cause of increased serum AFP, rather than necrosis or active regeneration.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10361518     DOI: 10.1093/ajcp/111.6.811

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  18 in total

1.  Determinants of serum alpha-fetoprotein levels in hepatitis C-infected patients.

Authors:  Peter Richardson; Zhigang Duan; Jennifer Kramer; Jessica A Davila; Gia L Tyson; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2011-12-07       Impact factor: 11.382

2.  Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma.

Authors:  Yasushi Tamura; Masato Igarashi; Hirokazu Kawai; Takeshi Suda; Shinji Satomura; Yutaka Aoyagi
Journal:  Dig Dis Sci       Date:  2010-04-21       Impact factor: 3.199

3.  Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development.

Authors:  Yasuto Takeuchi; Fusao Ikeda; Toshiya Osawa; Yasuyuki Araki; Kouichi Takaguchi; Youichi Morimoto; Noriaki Hashimoto; Kousaku Sakaguchi; Tatsuro Sakata; Masaharu Ando; Yasuhiro Makino; Shuji Matsumura; Hiroki Takayama; Hiroyuki Seki; Shintarou Nanba; Yuki Moritou; Tetsuya Yasunaka; Hideki Ohnishi; Akinobu Takaki; Kazuhiro Nouso; Yoshiaki Iwasaki; Kazuhide Yamamoto
Journal:  World J Hepatol       Date:  2015-09-08

4.  Value of highly sensitive fucosylated fraction of alpha-fetoprotein for prediction of hepatocellular carcinoma recurrence after curative treatment.

Authors:  Yasushi Tamura; Takeshi Suda; Shigeki Arii; Michio Sata; Fuminori Moriyasu; Hiroshi Imamura; Seiji Kawasaki; Namiki Izumi; Tadatoshi Takayama; Norihiro Kokudo; Masakazu Yamamoto; Hiroko Iijima; Yutaka Aoyagi
Journal:  Dig Dis Sci       Date:  2013-04-18       Impact factor: 3.199

5.  Serum alpha-fetoprotein levels during and after interferon therapy and the development of hepatocellular carcinoma in patients with chronic hepatitis C.

Authors:  Yasushi Tamura; Satoshi Yamagiwa; Yohei Aoki; So Kurita; Takeshi Suda; Shogo Ohkoshi; Minoru Nomoto; Yutaka Aoyagi
Journal:  Dig Dis Sci       Date:  2008-12-18       Impact factor: 3.199

6.  Serum α-fetoprotein levels in liver steatosis.

Authors:  Ayşegül Babalı; Erman Cakal; Tuğrul Purnak; Ibrahim Bıyıkoğlu; Başak Cakal; Osman Yüksel; Seyfettin Köklü
Journal:  Hepatol Int       Date:  2009-11-05       Impact factor: 6.047

Review 7.  Alpha-fetoprotein: a renaissance.

Authors:  A A Terentiev; N T Moldogazieva
Journal:  Tumour Biol       Date:  2013-06-14

8.  Association between serum alpha-fetoprotein levels and fatty liver disease: a cross-sectional study.

Authors:  Ping Xu; Cheng-Fu Xu; Xing-Yong Wan; Chao-Hui Yu; Chao Shen; Peng Chen; Gen-Yun Xu; You-Ming Li
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

9.  Direct acting antiviral-induced dynamic reduction of serum α fetoprotein in hepatitis C patients without hepatocellular carcinoma.

Authors:  Tung Huynh; Ke-Qin Hu
Journal:  Front Med       Date:  2019-10-26       Impact factor: 4.592

10.  Two patients with extremely elevated tumor markers: where is the malignancy?

Authors:  Patrick P J van der Veek; Wouter H de Vos Tot Nederveen Cappel; Alexandra M J Langers; Bart van Hoek
Journal:  Gastroenterol Res Pract       Date:  2011-06-16       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.